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During the type-setting of the final version of the article [1] some of the additional files were swapped. The correct
files are republished in this Erratum.Erratum
During the type-setting of the final version of the article [1]
some of the additional files were swapped (with the legends
remaining correct):
Additional File 1 was published under Additional File 3
hyperlink;
Additional File 2 was published under Additional File 1
hyperlink;
Additional File 3 was published under Additional File 2
hyperlink.
Additional Files 4–9 are all correct. The editors
apologize for the clerical mistake that led to the
mismatch of the additional files.
Additionally, the authors, based on the input from the
readers, wish to expand some of the descriptions of the
experimental procedures in the Additional File 1. In the
section describing the mutation status analysis the
authors added the following:
“For the alignment, pairs of Fastq files (i.e. R1 & R2)
sequenced from the same sample were aligned separately
using bwa aln & bwa sampe (default parameters) to the
hg19 (GRCh37) reference. Each pair of Fastq files gener-
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unless otherwise stated.same sample were merged to generate a single BAM file
representing all reads from the sequencing run. Using
the GATK routine CountCovariates, the merged BAM
file was subsequently analyzed to generate the covariates
necessary to perform base quality recalibration. Briefly,
it searches for mismatching bases in reads that do not
overlap known heterozygous sites (1,000 genomes +
dbSNP) and collects information on the mismatching
base’s quality and a series of other covariates (e.g. base
quality, read group, neighboring bases, sequencing
cycle). Using the GATK routine TableRecalibration, the
recalibration metrics obtained from CountCovariates
were used to recalibrate all base qualities from the BAM
file. This step is necessary as the base qualities generated
by the sequencer often inaccurately reflect the true
frequency of mismatching bases. The BAM files with
base quality recalibration are the files used in all post-
processing steps.
For mutation calling, allele counts and their associated
base qualities were collected for each individual cell line.
Only alleles fulfilling the following criteria were used in
subsequent steps: base quality (BQ) > = 10; neighbor-
hood base quality (NBQ) > = 10; mapping quality of as-
sociated read (MQ) > = 20; and its associated read is not
a duplicate. Any base quality exceeding the read’s mapping
quality is reduced to the read’s mapping quality. Positions
with less than 2 reads supporting any non-reference allele
were deemed homozygous reference and excluded from
further analyses. The likelihoods of all possible genotypes
(AA, AT, AC, etc.) given the allelic data collected for thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ginally defined in (11) and now available in the samtools
source code. The genotype likelihoods were then used in a
Bayesian model incorporating a prior probability on the
reference, and the heterozygous rate of the human gen-
ome. The genotype with the highest likelihood given the
data was chosen as most likely. No further analysis was
performed at this position for a homozygous reference
genotype. Otherwise, the following metrics were com-
puted at the variant position and used for post-processing
filtering of all putative variants: DP: Total read depth, AD:
Depth or coverage for all alleles, including alleles not in
genotype; BQ: Average base quality of each allele; MQ:
Average mapping quality of reads supporting each allele;
MQ0: Number of mapping quality zero reads overlapping
position; MQL: Number of ‘low’ mapping quality reads
overlapping position; NAHP: Average number of adjacent
homopolymer runs on either side of each allele in geno-
type; MAHP: Longest adjacent homopolymer run on ei-
ther side of each allele in genotype; AMM: Average
number of mismatches in reads supporting each allele;
MMQS: Average sum of the base qualities for all mis-
matching bases; DETP: Average effective distance to 3’
end of read for each allele, normalized by read length;
LD/MD/RD: Number of reads supporting each allele
where the allele is located in the left-most third of read,
middle-third of read, or right-most third of read, respect-
ively; LDS/MDS/RDS: Strand-aware version of above;
SB: Number of reads supporting each allele aligned to the
forward strand; and PN/NN: Previous and next nucleo-
tides in reference.
Since no normal control is available for our cell lines,
all variants were considered germline and the genotype’s
log-likelihood was used to compute a Phred-scaled qual-
ity/confidence of the germline variant. All putative vari-
ants and associated metrics were converted to the VCF
format, with the following filters applied to each variant:
conf: Genotype quality > = 100; dp: Total depth > = 8;
mdp: Maximum depth < 800; mq0: MQ0 < 5; mql:
MQL < 5; sb: Mutant allele strand bias p-value > 0.005
(Binomial test); mmqs: MMQS < = 20; amm: AMM < =
1.5; detp: 0.2 < = DETP < = 0.8; ad: AD of mutant
allele > = 4; and ma: More than two alleles have read
support > = 2. Variants that pass all filters were marked
PASS in the FILTER column of their VCF record.
Otherwise, the names of each filter that the variant
does not meet were recorded in the FILTER column.
Read coverage was calculated using a dynamic win-
dowing approach that expands and contracts the win-
dow’s genomic width according to the local read density
in the sample’s sequence. When the window’s read count
exceeds a user-defined threshold, the window’s size and
location, the raw read count, N, and the average cover-
age of the window, N / window size, were recorded.”The correct Additional files 1, 2 and 3, which include
the expanded description of the methods, are published
below.
Additional files
Additional file 1: Supplementary Methods, Supplementary Results,
Figures S1 to S10, and Tables S4, S6, S8, S9, S10, S12, and S13.
Supplementary Methods: detailed description of the therapeutic
compound response data, molecular data for the breast cancer cell lines,
molecular data for the external breast cancer tumor samples used for
validation, classification methods, data integration approach, statistical
methods, and pathway overrepresentation analysis. Supplementary
Results: assessment of cell line signal in tumor samples, inter-data
relationships, prediction comparison of datasets, validation against
other cell line datasets, and the patient response prediction toolbox
for the R project for statistical computing. Table S4: overview of
genes with good correlation (FDR P-value <0.05) between SNP6 and
gene expression; 22 to 39% of genes in copy number aberration
regions show a significant concordance between their genomic and
transcriptomic profile after multiple testing correction. Table S6: data
type ranking of the importance of the molecular datasets by comparison of
prediction performance of LS-SVM and RF classifiers built on individual data
sets and their combination, and by comparison of the average appearance
of data types in the top 100 of ranked features, with and without inclusion
of RPPA data. Examples are also provided of compounds for which (most)
datasets give similar results or for which one dataset performs better (shown
in bold). Table S8: performance for 'splice-specific' response predictors (RF)
with an AUC increase >0.05 when comparing all transcript features to
gene-level values alone. Table S9: statistical association between clinical
variables and predicted response for 306 TCGA patients with expression,
methylation and copy number data available. For each compound, the best
performing model was utilized (LS-SVM or RF with any combination of
expression, copy number and methylation data). Table S10: resistant/
intermediate/sensitive cutoffs for 22 compounds with model AUC >0.7
and at least one patient with probability of response >0.65. Cutoff value
1 separates patients considered resistant from intermediate. Cutoff value
2 separates patients considered intermediate from sensitive. The percentage
value for each group indicates the percentage of total patients (n = 306) in
each group. Table S12: presence and variance of filtered features from
U133A and exon array cell line data in tumor samples. Features from U133A
and the exon array that passed the variance and presence filter in the cell
lines were present in the majority of breast cancer tumor samples.
Table S13: summary of 167 predictors in random forests classifier for
lapatinib (all data types, optimal predictor number). Figure S1: data
summary in terms of number of features before and after data-type-specific
reduction and unsupervised filtering based on variance and signal detection
above background. Figure S2: overview of the mutation prevalence in the
cell line panel and TCGA data set for the list of seven common coding
variants detected by TCGA, with a distinction between luminal, basal and
ERBB2-enriched. Cell lines with unknown subtype are displayed in orange.
To make the subtypes comparable, luminal A and B were grouped into
luminal for the TCGA data set, whilst basal and claudin-low cell lines were
grouped into basal. The mutation rate in TCGA and the cell line panel shows
a similar distribution across the subtypes. Figure S3: comparison of the best
LS-SVM and RF models for the 90 compounds, sorted according to highest
AUC obtained with either model. Figure S4: validation of the cell line
signature for vorinostat in tumor samples grown in three dimensions:
heatmap of the 150-gene signature for vorinostat in the cell line panel
and 13 tumor samples treated with valproic acid. Seven out of eight
sensitive samples (87.5%) and four out of five resistant samples (80%)
are classified correctly with a probability threshold of 0.5 for response
dichotomization. Figure S5: predicted probability of response of TCGA
tumor samples to compounds lapatinib, sigma AKT1-2 inhibitor, GSK2126458
and docetaxel. The TCGA tumor samples are ordered according to increasing
probability of response. Figure S6: correlation-based coherence heatmap for
two cell line-derived gene signatures: coherence among 67 genes of the
U133A signature for the sigma AKT1-2 inhibitor in the cell lines (left) and
TCGA tumor samples (right) (Jaccard coefficient = 0.85; P-value <0.0001);
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cell lines (left) and TCGA tumor samples (right) (Jaccard coefficient = 0.79;
P-value <0.0001). Figure S7: comparison of the best model per dataset for
the 90 compounds, sorted according to highest AUC obtained with either
model (LS-SVM or RF). For RNAseq and exon array, the highest AUC is shown
among models built on gene-level data only or all features (exons, junctions,
and so on). Figure S8: distributions of response probabilities for 5-FU
determined by mixed model clustering and used for cutoff selection.
With a cutoff of 0.74, 23.9% of TCGA tumor samples were predicted to
respond to 5-FU (Table S10 in Additional file 1). Figure S9: association
between response to lapatinib and ERBB2 status, response to BIBW2992
and ERBB2 status, and response to tamoxifen and ER status for 306
TCGA patients with expression, methylation and copy number data
available. Figure S10: heatmap of the 167 highest ranked features for
lapatinib, obtained with RF applied to the full set of molecular data.
Additional file 2: Table S1. Overview of 84 cell lines with subtype
information and available data. GI50 values for 90 therapeutic compounds
are provided for 70/84 cell lines included in all analyses.
Additional file 3: Table S2. Processed Reverse Protein Lysate Array
(RPPA) intensity data for 70 (phospho)proteins with fully validated
antibodies in 49 cell lines. See Supplementary Methods in Additional file
1 for data processing details.
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